You are here

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Research Article
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Authors

  • Hans-Georg Rammensee Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany PubMed articlesGoogle scholar articles
  • Karl-Heinz Wiesmüller EMC microcollections GmbH Tübingen Germany PubMed articlesGoogle scholar articles
  • P. Anoop Chandran Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Henning Zelba Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Elisa Rusch Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Cécile Gouttefangeas Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany PubMed articlesGoogle scholar articles
  • Daniel J. Kowalewski Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany Present address: Immatics Biotechnologies GmbH Tübingen Germany PubMed articlesGoogle scholar articles
  • Moreno Di Marco Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Sebastian P. Haen Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Department of Oncology, Hematology, Immunology, Rheumatology and PulmonologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Juliane S. Walz Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Department of Oncology, Hematology, Immunology, Rheumatology and PulmonologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Yamel Cardona Gloria Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Johanna Bödder Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Jill-Marie Schertel Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany PubMed articlesGoogle scholar articles
  • Antje Tunger Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, GermanyFaculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany and Helmholtz Association/ Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Dresden Germany PubMed articlesGoogle scholar articles
  • Luise Müller Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany PubMed articlesGoogle scholar articles
  • Maximilian Kießler Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany PubMed articlesGoogle scholar articles
  • Rebekka Wehner Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, GermanyFaculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany and Helmholtz Association/ Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Dresden Germany German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg Germany PubMed articlesGoogle scholar articles
  • Marc Schmitz Faculty of Medicine Carl Gustav Carus, Institute of ImmunologyTechnische Universität Dresden Dresden Germany National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, GermanyFaculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany and Helmholtz Association/ Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Dresden Germany German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg Germany PubMed articlesGoogle scholar articles
  • Meike Jakobi NMI Natural and Medical Sciences Institute at the University of Tübingen Reutlingen Germany PubMed articlesGoogle scholar articles
  • Nicole Schneiderhan-Marra NMI Natural and Medical Sciences Institute at the University of Tübingen Reutlingen Germany PubMed articlesGoogle scholar articles
  • Reinhild Klein Department of Oncology, Hematology, Immunology, Rheumatology and PulmonologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Karoline Laske Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Kerstin Artzner Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany PubMed articlesGoogle scholar articles
  • Linus Backert Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany Present address: Immatics Biotechnologies GmbH Tübingen Germany PubMed articlesGoogle scholar articles
  • Heiko Schuster Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany Present address: Immatics Biotechnologies GmbH Tübingen Germany PubMed articlesGoogle scholar articles
  • Johannes Schwenck Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Department of Nuclear Medicine and Clinical Molecular ImagingUniversity Hospital of Tübingen Tübingen Germany Werner Siemens Imaging Center, Medical FacultyUniversity of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Alexander N. R. Weber Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany PubMed articlesGoogle scholar articles
  • Bernd J. Pichler Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Werner Siemens Imaging Center, Medical FacultyUniversity of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Manfred Kneilling Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Werner Siemens Imaging Center, Medical FacultyUniversity of Tübingen Tübingen Germany Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Christian la Fougère German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Department of Nuclear Medicine and Clinical Molecular ImagingUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Stephan Forchhammer Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Gisela Metzler Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Jürgen Bauer Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Benjamin Weide Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Wilfried Schippert Department of DermatologyUniversity Hospital of Tübingen Tübingen Germany PubMed articlesGoogle scholar articles
  • Stefan Stevanović Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany PubMed articlesGoogle scholar articles
  • Markus W. Löffler Department of Immunology, Institute for Cell BiologyUniversity of Tübingen Auf der Morgenstelle 15 72076 Tübingen Germany German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen Tübingen Germany Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”University of Tübingen Tubingen Germany Department of General, Visceral and Transplant SurgeryUniversity Hospital of Tübingen Tübingen Germany Department of Clinical PharmacologyUniversity Hospital Tübingen Tübingen Germany PubMed articlesGoogle scholar articles

Citation

Rammensee H, Wiesmüller K, Chandran PA, et al
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
Journal for ImmunoTherapy of Cancer 2019;7:307. doi: 10.1186/s40425-019-0796-5
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.